Close Menu

NEW YORK (GenomeWeb) – The Centre for Drug Research and Development (CDRD), a Canadian national drug development and commercialization center, said today that it has spun out a company, Sepset Biosciences, that's developing a rapid diagnostic blood test with an objective to provide early, targeted treatment for sepsis.

The blood test, which is founded on work led by University of British Columbia researcher Robert Hancock, detects a unique biomarker signature based on the body's immune response, rather than the presence of a pathogen.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Mar
18
Sponsored by
Thermo Fisher Scientific

Viruses mutate as they strive to thrive in response to selective pressures.

Mar
29
Sponsored by
Thermo Fisher Scientific

Global genetic surveillance is vital for understanding the evolution of viral pathogens and monitoring for changes in transmissibility, virulence, disease pathology, and impact on the efficacy of diagnostic tests, therapeutics, and vaccines.

Mar
31
Sponsored by
MilliporeSigma

This webinar will outline the development and commercialization journey of a novel CRISPR-based SARS-CoV-2 test.